Posted by MD Biosciences on Wed, Jun 16, 2010 @ 11:21 AM
Wednesday, June 16, 2010, St. Paul, MN - MD Biosciences, a Preclinical Contract Research Organization (CRO), offers in vivo models for the study of myocardial infarct (MI). The occlusion-induced myocardial infarct model is a well-known technique for investigating the cardio-protection of a drug therapy in the event of ischemia/reperfusion injury. The advantage of the model is the ability to study the functional relevance of a drug treatment on the heart following direct coronary flow and the mechanisms by which the drug promotes myocardial protection.
Occlusion-induced Ischemia Reperfusion Injury
Occlusion of the left coronary artery is performed to mimic myocardial infarction in humans that results from occlusion of arteriosclerotic plaques of coronary arteries. Using this model, scientists can get a better understanding of the functional, structural and molecular changes associated with clinical ischemic heart disease as well as investigate the cardio-protection of potential drug therapies. Following the 45 minutes of LAD occlusion, the LAD is opened and coronary blood flow is allowed. Therefore, any IV dosed drug will reach the heart tissue and the infarct area immediately.
Figure: Histology on four heart tissue samples from a vehicle treated group (A-B) and an active compound group (C-D) in the occlusion-induced ischemia reperfusion injury model. Occlusion duration was 45 minutes and reperfusion was over 48 hours. Slides A-D: transverse section of the heart at 0.5x magnification. Slides E-H: 4x magnification of slides A-D showing the scarred myocardium.
Study design can be customized to determine the duration of reperfusion following a 45-minute occlusion period. Readouts of the occlusion-induced ischemia-reperfusion injury model include histology of the heart as well as CPK and Troponin levels, which are relevant blood markers of myocardial infarction.
For more information and data on the occlusion-induced IR injury model, download the Whitepaper Myocardial Infarct models for evaluating the myocardial protection or potential drug therapies.
About MD Biosciences
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.
--------
The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Mon, Oct 05, 2009 @ 10:51 AM
MD Biosciences (MDB), a contract research organization offering
pre-clinical services and products in support of drug discovery for
inflammatory and neurological diseases, relocated its U.S. office from
1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on
October 3, 2009. The new location equips MD Biosciences with more lab
space, allowing for increased capacity for in vitro services and
product development and manufacturing to increase product offering.
Eddie
Moradian, President of MD Biosciences states, "At MD Biosciences, we
have always promised our clients that we will meet their needs now and
in the future; our expansion ensures that commitment. We doubled our
lab space so that we are able to provide 150 percent more services and
increase product development by 130 percent in the coming year in
comparison with the last.
Our relocation is just one step of
many in the endeavor to continue to offer the highest quality services
and products in assisting our customers in meeting their objectives.
Future projections include adding more highly specialized scientists to
our team and increasing our focus on our available products and
proprietary reagents."
About MD BiosciencesMD
Biosciences provides products and pre-clinical services, which include
efficacy testing, mode of action platforms, in vitro analysis,
histology and imaging for the Pharmaceutical, Medical Device and Animal
Health & Nutrition Industries. We offer several novel models in the
area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD,
pain, and Parkinson's disease. The in-depth expertise in these disease
models has been applied to designing protocols to assess the efficacy
and required dosage of novel compounds. Contracted studies are designed
and reviewed by MDB’s panel of internationally recognized experts and
performed at one of MDB’s specialized laboratories located in St. Paul,
MN (USA), Glasgow (Scotland) or in Israel . We provide a ready team of
experts to tackle problems and provide solutions. MDB also supplies for
purchase by all laboratories many of the products and proprietary
reagents used in our research, regardless of whether MDB is contracted
as a research organization. This allows our clients to optimize their
own research process by selecting steps to be performed by MDB and
research to be performed in-house.
###
The
information in this press release should be considered accurate only as
of the date of the release. MD Biosciences has no intention of updating
and specifically disclaims any duty to update the information in these
press releases.